contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


pci-biotech-invitation-to-first-half-2025-results-presentation-and-corporate-update

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

PCI Biotech Holding is a biopharmaceutical group, where most of the operations are conducted within the subsidiary PCI Biotech. The group is engaged in the development of therapeutic products based on the proprietary PCI technology. The solutions are intended for use in the treatment of cancer patients. PCI Biotech was originally founded in 2000 as a subsidiary of Photocure and is headquartered in Oslo, Norway.

PCI Biotech Holding

Oslo, Norway, 26 August 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2025 interim report on Friday, 29 August 2025, 08:30am – 09:00am CET (local...

Oslo, Norway, 26 August 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2025 interim report on Friday, 29 August 2025, 08:30am – 09:00am CET (local time).&nbsp; The presentation will be held in Norwegian as a live webcast available through www.pcibiotech.com. There will be a Q&amp;A session at the end of the presentation. Please submit questions to <a href="https://www.globenewswire.com/Tracker?data=PABxsftZ8rx72TYVIrCGUDlvbUFMgPwhbRNzfyRkkQi27QLJoozMR_X96oKs7oqXflNwiWii2tvBWz_DRUKXfn61sKVX3MHWxvGGaci9xs0=">post@pcibiotech.no</a> prior to the webcast. It will be possible to post written questions through the webcast console during the session. The interim report and presentation will be made available on www.newsweb.no and on the company's webpage, www.pcibiotech.com, from 07.00am CET the same day. For further information, please contact: Ronny Skuggedal, CEO / CFO Email: rs@pcibiotech.no Mobile: +47 9400 5757 For further information, please visit: www.pcibiotech.com&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact information:&nbsp;PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Forward-looking statements&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. <img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTEyNDczOSM0MDIyMDM3MzYjMjAwMjk3Nw==" alt=""> <img src="https://ml-eu.globenewswire.com/media/ZmI0NzliOTItNDRmMi00MGU5LWI1NWItN2E1MzIzOWZmOGYzLTEwMTQ1NTAtMjAyNS0wOC0yNi1lbg==/tiny/PCI-Biotech-Holding-ASA.png" alt="">

PCI Biotech: Invitation to first half 2025 results presentation and corporate update